Pharmaceutical

Friday, 24 July 2015

Asia Pacific Region to Dominate the Global FMD Vaccines Market

Transparency Market Research has released a new report on the global foot and mouth disease (FMD) vaccines market, which forecasts the growth of the overall FMD vaccines market at a CAGR of 8.8% during the period from 2014 to 2020. The FMD vaccines market was valued at US$0.51 billion in 2013. Due to the increasing frequency of FMD outbreaks, the report projects that the market will reach a worth of US$0.95 billion by the end of 2020. The report is titled ‘Foot and Mouth Disease Vaccines Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 – 2020’.

Browse the full Foot and Mouth Disease Vaccines Market Report at http://www.transparencymarketresearch.com/foot-mouth-disease-vaccines.html

Caused by Aphthovirus, FMD is highly infectious viral disease which affects cloven-hoofed animals and leads to high mortality rate among the young stock such as lambs and piglets. The high prevalence of FMD across the globe affects the international trade in livestock products. The report provides an overview of the overall global FMD vaccines market and evaluates the growth drivers and restraints. Favorable government initiatives to control FMD outbreaks have boosted the growth of the global FMD vaccines market. Also, rising consumption of meat and dairy products demands healthy livestock, which has further fuelled the need for FMD vaccines. The report mentions that the involvement by various governments in purchasing FMD vaccines will lead to the dip in cost which will negatively affect the global FMD vaccines market in terms of revenue. FMD is caused by seven different types of serotype and the current vaccines are serotype-specific. Unpredictable serotype outbreaks can hamper the growth of the global FMD vaccines market. The report indicates that DNA vaccines will open new opportunities for the market during the forecast period.

Depending upon the type of vaccines, the report segments the global FMD vaccines market into conventional vaccines and emergency vaccines. The conventional vaccines have been further categorized into aluminum hydroxide or Saponin based vaccines, and oil-based vaccines. In 2013, oil-based FMD vaccines dominated the global FMD vaccines market with a market share of 63%, owing to its high efficiency and longer effect in treating the disease.

On the basis of application on the livestock, the global FMD vaccines market has been divided into cattle, pigs, sheep and goats, and others. To meet the increasing demand for milk and meat, cattle are reared the most across the globe, owing to which it has emerged as the largest application segment of the global FMD vaccines market. In Middle-east, as pork consumption is prohibited, the cattle segments contribute significantly to the FMD vaccines market of the region. The report predicts that the cattle segment will exhibit the fastest growth during the forecast horizon.

Browse the full Press Release Report:

http://www.transparencymarketresearch.com/pressrelease/foot-mouth-disease-vaccines.htm

Geographically, the global FMD vaccines market has been segmented into four key regions: Europe, North America, Asia Pacific, and Rest of the World. As the disease is non-existent in North America and Europe, the scope of the growth of the vaccines market in these regions is negligible. Due to frequent outbreaks of FMD in Asia Pacific region, the global FMD vaccines market has been dominated by this region with more than 70% share. The report documents the market revenue in China, India, Malaysia, South Korea, and rest of APAC during the forecast period. The report profiles some of the key vendors of the global FMD vaccines market such as Indian Immunologicals Ltd., Bayer AG, Agrovet Co., and Brilliant Bio Pharma Ltd.

Request a Brochure of this Report: http://www.transparencymarketresearch.com/sample/sample.php?flag=s&rep_id=2480

About Us

Transparency Market Research (TMR) is a global market intelligence company providing business information reports and services. The company’s exclusive blend of quantitative forecasting and trend analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants use proprietary data sources and various tools and techniques to gather and analyze information.

TMR’s data repository is continuously updated and revised by a team of research experts so that it always reflects the latest trends and information. With extensive research and analysis capabilities, Transparency Market Research employs rigorous primary and secondary research techniques to develop distinctive data sets and research material for business reports.

Global Tuberculosis Testing Market Finds Encouragement in Growing Healthcare Efforts

The global tuberculosis testing market continues to grow as governments and institutions across the globe continue to make efforts to eradicate this deadly communicable disease. Statistics gathered by the WHO state that 9 million people acquired tuberculosis (TB) in 2013 and 1.5 met a fatal end, out of which 360,000 were HIV positive. These figures are declining with each passing year thanks to the increasingly effective diagnosis and treatment options offered to patients. It is estimated that such initiatives were able to save the lives of 37 million tuberculosis patients between 2000 and 2013.

Browse Full Global Tuberculosis Testing Market Report With Complete TOC @ http://www.transparencymarketresearch.com/tuberculosis-testing-market.html

Tuberculosis can be broken down into two types, namely active disease, which can transform to multi-drug resistant TB or MDR-TB, and latent disease. Tuberculosis also has a rare form called miliary TB, which occurs when TB infection finds its way to the bloodstream. The priority steps to counter MDR-TB are supreme quality of treatment for drug-susceptible TB to avert MDR-TB, expanding the reach of testing and detection of MDR-TB cases to remote regions, simplifying the access to good healthcare, infection control, and strengthening the political commitment, especially in BRIC nations, which constitute 50% of global TB cases.

Dedicated Efforts of Non-profit Organizations Drive Global Tuberculosis Testing Market

The efforts taken by governments, social activists, and several healthcare institutions have translated into positive results. A ripple effect of these efforts can also be seen in the growth of the global tuberculosis testing market. The global tuberculosis testing market was worth US$1,936.1 million in 2013. By 2020 this market is expected to reach a valuation of US$2,619.4 million, growing at a promising CAGR of 4.3% from 2014 to 2020.

The factors driving this gigantic growth are the rising number of tuberculosis cases, increasing acceptance of innovative methods for treating tuberculosis, and enhanced molecular and rapid culture diagnostic tests. The serious involvement and dedicated efforts of non-profit healthcare organizations are further boosting the global tuberculosis testing market. Growing tuberculosis cases have also resulted in increased research and development budgets, encouraging manufacturers to launch better testing technologies.

Serological Tests and IGRA Sub-segments to Grow the Fastest

The global tuberculosis testing market is classified on the basis of type and geography. The segments by product type are culture-based tests, smear microscopy, nucleic acid testing, radiography (chest x-ray), Mantoux test (tuberculin skin test), drug susceptibility test (DST), and other tests such as serological tests, ADA, and IGRA. Geographically, the global tuberculosis testing market is fragmented into North America, Asia Pacific, Europe, and Rest of the World.

Browse Full Press Release report http://www.transparencymarketresearch.com/pressrelease/tuberculosis-testing-market.htm

Out of these segments, culture-based tests hold a lion’s share in the global tuberculosis testing market. These tests are inclusive of both solid and liquid culture tests. Analysts predict that other segments such as serological tests and IGRA will grow rapidly in the coming five years as well. All of these tuberculosis testing methods generate quick results, offer improved accuracy, and require the patient to just one visit.

India and China to Make Steady Contribution to Growth of Global Tuberculosis Market

Geographically, Asia Pacific led the global tuberculosis testing market in 2013, closely followed by North America. The prime factor driving the unprecedented growth rate in Asia Pacific is a huge patient pool, which continues to grow at a rapid rate, especially in countries such as China and India. Though North America has a smaller patient pool, the tuberculosis testing market is expected to grow in this region due to increasing awareness, better healthcare infrastructure, and growing acceptance and adoption of expensive TB tests due to improving purchasing power of patients.

Some of the key players in the global tuberculosis testing market are Akonni Biosystems Inc., Abbott Laboratories, Becton, Alere Inc., Dickinson and Company, Cepheid, Epistem plc, bioMérieux SA, F. Hoffmann-La Roche Ltd., Hologic, QIAGEN, Hain Lifescience GmbH, Sanofi, and Thermo Fisher Scientific Inc.

Request a Brochure of this Report: http://www.transparencymarketresearch.com/sample/sample.php?flag=s&rep_id=2267

About Us

Transparency Market Research is a global market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants, use proprietary data sources and various tools and techniques to gather, and analyze information.

Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

Contact

Mr. Nachiket Ghumare

90 State Street, Suite 700

Albany, NY 12207

Tel: +1-518-618-1030

USA - Canada Toll Free: 866-552-3453

Email: sales@transparencymarketresearch.com

Website: http://www.transparencymarketresearch.com

Thursday, 23 July 2015

At 0.3% CAGR, Global Antibacterial Drugs Market to Stagnate due to Emergence of Drug-Resistant Bacterial Strains

A new research report from U.S.-based Transparency Market Research examines the global antibacterial drugs market and arrives at studied conclusions about the market’s expected trajectory during the forecast period 2013-2019. The report states that the global market for antibacterial drugs was worth US$43.55 billion in 2012. Helped by factors such as the growing prevalence of bacterial diseases around the world and growth in geriatric population with weakened immune systems due to age, the market is expected to rise at a 0.3% CAGR from 2013 to 2019, to eventually reach a total value of US$45.09 billion.The report, titled ‘Antibacterial Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019’, draws on extensive primary and secondary research to formulate conclusions, employing trusted analytical tools such as Porter’s five forces analysis, market attractiveness analysis, and SWOT analysis.

Browse the full Antibacterial Drugs Market Report at http://www.transparencymarketresearch.com/antibacterial-drugs-market.html

Porter’s five forces analysis reveals the tussle between the established players and new entrants, threat to branded products from substitutes, and the relative power of buyers and suppliers. Use of market attractiveness analysis helps develop the crucial part of the report: recommendations for market players regarding the feasibility of investment in the market in the forecast period. SWOT analysis helps expand upon the competitive landscape of the market, to provide a comparative overview of the major players operating in the global antibacterial drugs market.“Despite the strong factors working in its favor, the global antibacterial drugs market is restrained by a number of equally influential issues. This is the reason why the CAGR of the market is expected to remain negligible in the forecast period,” states a TMR analyst.

Browse the full Press Release :

http://www.transparencymarketresearch.com/pressrelease/antibacterial-drugs-market.htm

Major restraints acting on the antibacterial drugs market are the proliferation of generic drugs, aided by ongoing patent expiration of several blockbuster drugs, and rise in multi-drug resistant strains of pathogenic bacteria. The latter is exacerbated by the weak pipeline of novel antibacterial drugs at present, and can be resolved by increased funding on constantly evolving product development.The antibacterial drugs market is segmented into seven segments by drug class, of which B-Lactams emerged as the market leader in 2012, holding a whopping 57% share in the market. Quinolones, which were the second largest class of antibacterial drugs in the global market the same year, are expected to regress in the forecast period owing to heightened risk of complications due to the usage of this quinolones and impending patent expirations.Of pipeline antibacterial drugs, the report profiles the data regarding delafloxacin, surotomycin, ceftolozane/tazobactam, tedizolid, dalbavancin, CAZ AVI, oritavancin, and others. Forecasts for the development of these products till 2019 are presented in the report.

Among the major antibacterial drugs market players, the report examines the business operations, product catalog, and financial standing of companies such as Bayer AG, AstraZeneca, Eli Lilly, Johnson and Johnson, Merck, Sanofi, GSK, Sanofi, Pfizer, and Novartis. A comprehensive overview of the market’s competitive landscape is presented in the report to aid market stakeholders assess market conditions and modify their market strategies accordingly.

Request a Brochure of this Report: http://www.transparencymarketresearch.com/sample/sample.php?flag=s&rep_id=1567

About Us

Contact

Mr. Nachiket

State Tower,

90 State Street,

Suite 700,

Albany NY - 12207

United States

Tel: +1-518-618-1030

USA - Canada Toll Free: 866-552-3453

Email: sales@transparencymarketresearch.com

Website: http://www.transparencymarketresearch.com

Meningococcal Vaccines Market Expected to Reach USD 4.4 Billion Globally in 2022

According to a new report published by Transparency Market Research Meningococcal Vaccines Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2014 - 2022, the global meningococcal vaccines market was valued at USD 1.5 billion in 2013 and is expected to reach a value of USD 4.4 billion in 2022, growing at a CAGR of 12.4% from 2014 to 2022.

Browse the full Meningococcal Vaccines Market Report at http://www.transparencymarketresearch.com/meningococcal-vaccines-market.html

Meningococcal disease is caused by the bacterium Neisseria meningitidis and occurs sporadically throughout the world with seasonal variations. It accounts for a proportion of endemic bacterial meningitis, which can progress very rapidly leading to death within 24 hours from the onset of symptoms. The disease is often misinterpreted as common flu in most of the cases. Five out of the several serogroups are known to cause meningococcal disease. The serogroups responsible for causing the disease comprise A, B, C, Y and W-135. The causative agent N. meningitidis is commonly found in the nasopharynx of humans and gets transmitted through droplet inhalation by means of close contact such as exposure to smokers, crowded living conditions such as dormitories, certain inherited disorders of the immune system, functional/anatomical asplenia or through intimate oral contact among others. According to the European Federation of Pharmaceutical Industries and Association, every year, meningitis affects almost 500,000 people globally, primarily affecting toddlers, infants and young adults, due to weaker immune system.

The global market for meningococcal vaccines is segmented broadly into vaccine types namely, polysaccharide, conjugate, combination and Men B vaccines. The report also provides analysis for vaccine under development, NmVac4-DT by JN- International that is expected to be commercialized during the forecast period 2014 to 2022. The vaccine types are further segmented by different brands available in the market. The conjugate vaccines segment is likely to lead the overall meningococcal vaccines market in terms of revenue, which is estimated to be worth USD 3,127.2 million by 2022 at a CAGR of 11.1%. According to Department of Health, U.K., Bexsero is the first serogroup B vaccine to be incorporated into the national immunization program and is expected to be available in the market for sales post settle of price negotiations. The U.S. FDA recently approved two Men B vaccines: Trumenba by Pfizer in October 2014 and Bexsero by Novartis in January 2015.

The market for meningococcal vaccines is largely driven by increasing government intervention in reforming the healthcare infrastructure and incorporation of legislations specific to meningococcal vaccination. The public-private partnerships for conducting research and development, and manufacturing of quality vaccines at an affordable price are also contributing positively in driving market growth. Awareness campaigning from government and non-profit organizations, and obligatory immunization for individuals heading to Mecca (for Hajj pilgrimage) and the South African meningitis belt will also contribute to growth of this market. High cost of few but vital vaccines, such as Bexsero, and need for efficient cold chain logistics to maintain safety and efficacy of the vaccine are expected to be some of the major factors posing a challenge to the adequate uptake of these vaccines.

Browse the full Press Release report: http://www.transparencymarketresearch.com/pressrelease/meningococcal-vaccines-market.htm

The key players dominating the global meningococcal vaccines market include Sanofi Pasteur (the vaccine division of Sanofi SA), Novartis International AG and GSK plc. These players account for more than 90% of the meningococcal vaccines market. Players such as Serum Institute of India Ltd., JN International Medical Corporation, Biomed Pvt. Ltd., Nuron Biotech and Baxter account for the remaining market share.

The global meningococcal vaccines market is segmented as follow:

Meningococcal Vaccines Market, by Type

Polysaccharide Vaccines, by Brand

Menomune

Mencevax

NmVac4

Others

Quadri Meningo

Bi Meningo

Conjugate Vaccines, by Brand

Menactra

Menveo

NeisVac-C

Nimenrix

Meningitec

Menjugate

MenAfriVac

NmVac4-DT

Combination Vaccines, by Brand

MenHibrix

Menitorix

Men B Vaccines, by Brand

Bexsero

Trumenba

Meningococcal Vaccines Market, by Geography

North America

U.S.

Canada

Europe

U.K.

Germany

Rest of Europe

Asia Pacific

Japan

Australia

Rest of Asia Pacific

Rest of the World

Latin America

Africa

Rest of RoW

Request a Brochure of this Report: http://www.transparencymarketresearch.com/sample/sample.php?flag=s&rep_id=1666

About Us

Contact

Mr. Nachiket Ghumare

90 State Street, Suite 700

Albany, NY 12207

Tel: +1-518-618-1030

USA - Canada Toll Free: 866-552-3453

Email: sales@transparencymarketresearch.com

Website: http://www.transparencymarketresearch.com

Pharmacovigilance Market: Drive by Pharmaceutical Companies to Mitigate Risk Associated with Drugs to Bolster Growth

According to “Pharmacovigilance Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019”, a new research study by U.S.-based market research and intelligence firm Transparency Market Research, the global pharmacovigilance market that was valued at US$2,147.3 million in 2012 is estimated to be worth US$5,008.2 million by the end of 2019, growing at a CAGR of 12.9% during the forecast period from 2013 to 2019.

Browse the full Pharmacovigilance Market Report at http://www.transparencymarketresearch.com/pharmacovigilance-market.html

Stringent government regulations, issues pertaining to public safety, toughened inspection regimes, coupled with the need of patients to report ailments immediately, has propelled growth in the global pharmacovigilance market. The World Health Organization (WHO) defines pharmacovigilance as the science and activities which help detect, monitor, assess, and evaluate chances of any adverse occurrence or drug-related side effect from the consumption of the medicinal products. Pharmacovigilance activities are aimed to promote safer administration of drugs and other medicinal products. This is attained by generating awareness about the importance of timely, relevant, and precise clinical safety information related to medical products.

The global pharmaceutical industry is growing at a rapid pace and this has led to the innovation of a number of medicinal products that promote faster and more accurate treatment to several diseases and disorders. This range of new medicinal products comes along with many benefits, but none of these benefits are free from adverse drug reactions that can result in illness, disability and at times even death. Hence, early discovery of adverse drug reactions during clinical trials, clinical phase IV, or during post-marketing surveillance is very important in mitigating the risk of any unpleasant occurrences.

A majority of pharmaceutical companies nowadays are actively involved in assessing and monitoring drugs which are under clinical trial. In fact, new medicinal products that are marketed are also kept under vigilance by the companies. Apart from drugs, medicinal products such as traditional medicines, vaccines, medical devices, and blood products are also assessed and monitored during the different phases of their production and marketing.

The report has segmented the global pharmacovigilance market based on service providers, clinical trial phases and methods used for reporting drug safety. On the basis of clinical trial phases, the global market for pharmacovigilance can be categorized into pre-clinical studies, phase I, phase II, phase III, phase IV, and post-marketing surveillance. Among these segments, clinical trial phase IV accounted for almost 74.7% of the market share in 2012. The market for clinical trial phase IV in 2012 was valued at US$1,604.8 million.

Geographically, North America dominated the global pharmacovigilance market in 2012, however market trends indicate that Asia Pacific will register the highest rate of growth, a CAGR of 15.2%, during the forecast period from 2013 to 2019. Factors such as growing population, reduction in healthcare cost, and high patient enrollment will bolster demand for pharmacovigilance in the global market.

Browse the full Press Release Report: http://www.transparencymarketresearch.com/pressrelease/pharmacovigilance-market.htm

According to the publication, key players dominating the market includes companies such as Cognizant Technology Solutions, Pharmaceutical Product Development Inc. (PPD), Pfizer Inc., Novartis International AG, Accenture, Plc, Parexel International Corporation, Icon Plc., Quintiles Transnational Corporation, PRA International Inc., Bristol-Myers Squibb, Covance Inc., iGATE Corporation, and Wipro Limited.

Request a Brochure of this Report: http://www.transparencymarketresearch.com/sample/sample.php?flag=s&rep_id=1729

About Us

Tuesday, 21 July 2015

A Brief Report on the Steadily Growing and Technologically Advancing Global Albumin (Excipient) Market

Albumin today is a popular protein that is used for functions such as therapy, diagnosis, and also used as an excipient. The global albumin (excipient) market includes those that are most suited for stabilizing and protecting a drug during its many stages till it is administered. It protects an active pharmaceutical ingredient or a drug against degradations, aggregation, and oxidation. The excipient is present with the drug since the drug’s formulation and protects it during manufacturing, storage, and transportation. An excipient’s feasibility is checked through preformulation studies that check the interactions it has with the intended drug and the environment. An excipient may find vast areas of usability in drug formulation and delivery, along with the manufacture of vaccine and to provide a medium during vaccine production.

Browse Full Global Albumin Market Report With Complete TOC @ http://www.transparencymarketresearch.com/albumin-market.html

Albumin is one of the most popular excipients due to its relatively stable character which makes it easy to handle and store. One of the key advantages of using albumin is its intrinsic stability, due to which it can be heated to 60°C for 10 hours. This facilitates the inactivation of viruses during drug production.

Global Albumin Market Segmentation

The three categories of classifying the global albumin market are applications, type, and geography. By type, the market becomes:

Human Serum Albumin

Bovine Serum Albumin

Recombinant Albumin

Human serum albumin held the largest market share in 2013 and was worth US$476.7 million. The bovine serum albumin segment is the second largest, but faces restraining factors mostly concerning ethics. There have been many protests against the alleged cruel treatment of bovine fetuses in the process of obtaining bovine serum. Another restraining factor is the retention of certain amount of impurities in the albumin excipient. The issues with bovine serum albumin are proving to be more and more serious, prompting many researchers to search for alternatives. The fastest growing segment in the global albumin market by type is the recombinant albumin, with a CAGR of 2.7% within the forecast period of 2014 to 2020.

The global albumin market according to volume is segmented into:

Vaccines

Drug formulation and delivery

Components of medium

Browse the full Press Release Report: http://www.transparencymarketresearch.com/pressrelease/albumin-market.htm

The four general regions that are identified to function in the global albumin market are North America, Europe, Asia Pacific, and the Rest of the World.

Overall Market Drivers and Restraints

The major growth-improving factors in the global albumin market are improvements in product stability, the rapid growth of the recombinant albumin segment, and improvements in the purification technology of proteins. Researchers are gaining in quality and level of access to technology, promoting a faster rate of advancement.

On the other hand, the restraining factors in the global albumin market are just as serious. They include the shift in preference towards the use of chemically defined serum-free media that threatens to cut off avenues of development in the market. Animal cruelty protesters are also adding pressure against the bovine albumin segment, making it difficult for the segment to grow.

Key Companies

The leading players in the global albumin (excipient) market include Thermo Fisher Scientific, Sigma-Aldrich Corporation, RayBiotech Inc., Octapharma AG, Novozymes A/S, Mitsubishi Tanabe Pharma Corp., MedzBio Pte. Ltd., InVitria, HiMedia Laboratories Pvt. Ltd., and CSL Behring LLC.

The global albumin market is currently expected to grow at a CAGR of 2.3% through a time window of 2014 to 2020. The market was previously valued at US$704.9 million in 2013, and according to calculations, should reach a total worth of US$828.2 million by 2020. Improved product stability being its primary factor of growth, the market is set to expand itself in terms of product quality and demand.

Request a Brochure of this Report: http://www.transparencymarketresearch.com/sample/sample.php?flag=s&rep_id=3984

About Us

Contact

Mr. Nachiket Ghumare

90 State Street, Suite 700

Albany, NY 12207

Tel: +1-518-618-1030

USA - Canada Toll Free: 866-552-3453

Email: sales@transparencymarketresearch.com

Urgent Care Centers Market Flourishes as Patients Seek Basic Ambulatory Healthcare Solutions

The urgent care centers market is becoming an increasingly bigger part of the global health care system. It is a lucrative business model that is all about convenience for patients. As consumers look for less expensive healthcare options, urgent care centers and walk-in-clinics have been opening with greater frequency in various regions in recent years. Now-a-days, hospital systems also are increasingly expanding their networks into the urgent-care businesses by opening clinics at strategic locations in the world and buying out independent practices too. Moreover, the global urgent care centers market witnesses plenty of funding from private equity people who believe this is a gold rush for the forthcoming years.

Industry Insights into the Urgent Care Centers Market

Urgent care centers (UCCs) treat the most common illnesses and injuries – including cuts, back pain, colds, and ear infections. Such centers also take X-rays and perform simple urine, drug and blood tests on patients. However, UCCs do not provide critical care services and life-threatening surgeries. These centers are mainly considered as ambulatory healthcare centers such as convenient care clinics and emergency departments.

Browse Full Global Urgent Care Centers Market Report With Complete TOC @ http://www.transparencymarketresearch.com/urgent-care-centers-market.html

The urgent care center model is basically designed to provide cost-effective healthcare services and optimum quality to general public across the globe. Propelled by reduction in primary care appointments and frustration over long waits in hospitals and emergency rooms (for non-emergency care), the market has experienced a spurt of growth for urgent care facilities in the past few years. The number of medical facilities has increased from 8,000 to nearly 9,000 and consumers continue to yearn for similar immediate accessible medical care centers in many emerging regions of the world.

According to a market firm in the U.S. the UCCs market was valued at US$23.5 billion in 2013. Moderately growing at a CAGR of 3.8% from 2014 to 2020, the market is expected to reach US$30.5 billion by the end of 2020.

Such factors have been the driving force behind this monumental growth in the global urgent care centers market.

Services and Segmentations of UCC Market

The global urgent care centers market is broadly segmented on the basis of major services provided by medical centers. Some of the services listed in this market segment include, services for injury, trauma, illness, diagnostic, routine vaccination, physical, and screening and monitoring. Amongst them, the majority of the market share of revenue was generated by the illness services sector as of 2012. Most of the visits in the illness segment market in the same year were for conditions such as pharyngitis, urinary tract infections, upper respiratory tract infections, and fever and cold. The maximum number of illness related visits in 2012 was from the otitis media that accounted for more than 50%. However, the illness sector was followed by the injury segment in the global urgent care centers market. The UCCs market is widely fragmented with small and large players, wherein, the small players such as physician groups or physicians hold approximately 35% of the medical centers across various regions.

New Players will Find More Opportunities in Asia Pacific Region

Geographically, the global UCCs market is segmented into four major regions namely, Asia-Pacific, Europe, North America, and Rest of the World (RoW). North America once held the majority share of the overall UCCs market due to high adoption of UCCs for non-emergency conditions. This region is still expected to retain its position until the end of 2020.

Europe is at a distant second to this region in terms of growth and development regarding the walk-in health services and cost-effective medical care facilities. In the Asia-Pacific region, some of the major countries that offer high growth opportunities to existing and new companies in this market include India, China, Japan, New Zealand, and Australia.

Request a Brochure of this Report: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=2254

About Us

TMR is a U.S.-based market intelligence company driven by a global team of high-pedigree industry consultants, analysts, and researchers. TMR leverages its worldwide Syndicated Research, Custom Research, and Market Consulting expertise to help businesses make accurate decisions.

The company’s multi-disciplinary expertise has made it the preferred growth partner of hundreds of companies worldwide, from multibillion dollar conglomerates to emerging regional businesses. TMR’s exclusive blend of quantitative forecasting and trends analysis draws on proprietary data sources, tools, and techniques.